Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, in Healthy Volunteers and Patients with Cystic Fibrosis: A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study

Sivagurunathan Sutharsan,Kenneth Newman,Stuart Elborn,Wolfgang Gleiber,Shuling Guo,Rainald Fischer,Rosie Yu,Alex Horsley,Jeff Crosby

doi:10.2139/ssrn.4075836

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, in Healthy Volunteers and Patients with Cystic Fibrosis: A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study

Sivagurunathan Sutharsan, Kenneth Newman + Show 7 more

https://doi.org/10.2139/ssrn.4075836

Copy DOI

Journal: SSRN	Publication Date: Jan 1, 2022
Citations: 1

Affiliation: University of Duisburg-Essen, Ionis Pharmaceuticals (United States), Queen's University Belfast, Wythenshawe Hospital, University of Manchester, Institute of Infection and Immunity

#Cystic Fibrosis #Healthy Volunteers + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, in Healthy Volunteers and Patients with Cystic Fibrosis: A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study

Full Text